Phase 1 Double Blind, Placebo Controlled Study Assessing Safety and Activity Of 2 Escalating Doses of hMaxi-K Gene Transfer By Direct Injection Into the Bladder Wall In Female Subjects With OAB (Overactive Bladder Syndrome and Detrusor Overactivity)

Trial Profile

Phase 1 Double Blind, Placebo Controlled Study Assessing Safety and Activity Of 2 Escalating Doses of hMaxi-K Gene Transfer By Direct Injection Into the Bladder Wall In Female Subjects With OAB (Overactive Bladder Syndrome and Detrusor Overactivity)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Maxi-K gene therapy (Primary)
  • Indications Detrusor instability; Overactive bladder
  • Focus Adverse reactions
  • Sponsors Ion Channel Innovations
  • Most Recent Events

    • 03 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 24 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
    • 24 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Jul 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top